What is known about the mechanism of action of dimethyl fumarate in multiple sclerosis?

Dimethyl fumarate's therapeutic mechanism in multiple sclerosis is not fully understood; preclinical studies suggest its pharmacodynamic responses are primarily mediated by Nrf2 transcriptional pathway activation, and upregulation of Nrf2-dependent antioxidant genes has been demonstrated in patients.